March 23, 2017 11:28 PM ET

Biotechnology

Company Overview of Invitae Corporation

Company Overview

Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare in the United States, Canada, Israel, and internationally. The company processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. It provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. The company...

458 Brannan Street

San Francisco, CA 94107

United States

Founded in 2010

332 Employees

Phone:

415-374-7782

Key Executives for Invitae Corporation

Co-Founder, Chief Executive Officer, President and Director
Age: 42
Total Annual Compensation: $331.0K
Executive Chairman
Age: 58
Total Annual Compensation: $251.0K
Compensation as of Fiscal Year 2015.

Invitae Corporation Key Developments

Invitae Corporation Announces Availability of New Genetic Test for Diagnosis of Spinal Muscular Atrophy

Invitae Corporation announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA), a neuromuscular disease that is one of the lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, features a novel, custom methodology that offers significant improvements over current testing approaches. Accurate testing of both genes is critical for the diagnosis and treatment of SMA. Testing for the absence of functional SMN1 is the basis of diagnosis and can distinguish the condition from other neuromuscular diseases such as muscular dystrophy. Understanding the number of copies of the SMN2 gene can provide prognostic information and help guide therapeutic choices and clinical trial participation. However, due to the similarities between the two genes, testing is technically challenging and reliably accurate tests have not previously been widely available. Invitae's approach leverages advanced next generation sequencing and a customized bioinformatics solution to accurately identify sequence changes and copy number changes in both genes from a single test. Analysis of SMN1 and SMN2 is now available from Invitae as a stand-alone test, and it has been added to a number of the company's comprehensive neuromuscular and neuropathy panels, allowing physicians the ability to test for SMA alongside a number of other neurological disorders for no additional cost.

Invitae Corporation Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 04:00 PM

Invitae Corporation Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 04:00 PM. Venue: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Massachusetts, United States.

Invitae Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Invitae Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net loss of $24.8 million or $0.69 per basic and diluted share on revenue of $9.2 million compared to net loss of $24.3 million or $0.76 per basic and diluted share on revenue of $3.2 million reported in the same period last year. Loss from operations was $24.95 million against $24.3 million reported last year. For the year, the company reported net loss of $100.3 million or $3.02 per basic and diluted share on revenue of $25.15 million compared to net loss of $89.8 million or $3.18 per basic and diluted share on revenue of $8.4 million reported in the same period last year. Loss from operations was $100.2 million against $89.5 million reported last year. Cash used in operating activities in 2016 amounted to $76.3 million, as compared to $80.7 million in 2015.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 6, 2017
PatientCrossroads, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Invitae Corporation, please visit invitae.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.